In Vitro ELISA and Cell-Based Assays Confirm the Low Immunogenicity of VNAR Therapeutic Constructs in a Mouse Model of Human RA: An Encouraging Milestone to Further Clinical Drug Development

@article{Ubah2020InVE,
  title={In Vitro ELISA and Cell-Based Assays Confirm the Low Immunogenicity of VNAR Therapeutic Constructs in a Mouse Model of Human RA: An Encouraging Milestone to Further Clinical Drug Development},
  author={Obinna C. Ubah and Andrew J. Porter and C. Barelle},
  journal={Journal of Immunology Research},
  year={2020},
  volume={2020}
}
  • Obinna C. Ubah, Andrew J. Porter, C. Barelle
  • Published 2020
  • Medicine
  • Journal of Immunology Research
    • Anti-drug antibodies (ADAs), specific for biotherapeutic drugs, are associated with reduced serum drug levels and compromised therapeutic response. The impact of ADA on the bioavailability and clinical efficacy of blockbuster anti-hTNF-α monoclonal antibodies is well recognised, especially for adalimumab and infliximab treatments, with the large and complex molecular architecture of classical immunoglobulin antibody drugs, in part, responsible for the immunogenicity seen in patients. The… CONTINUE READING
    View on PubMed
    doi.org

    References

    SHOWING 1-10 OF 46 REFERENCES
    Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics
    • 58
    • PDF
    Immunogenicity of Anti-TNF-α Biotherapies: II. Clinical Relevance of Methods Used for Anti-Drug Antibody Detection
    • 47
    • Highly Influential
    • PDF
    An Anti-hTNF-α Variable New Antigen Receptor Format Demonstrates Superior in vivo Preclinical Efficacy to Humira® in a Transgenic Mouse Autoimmune Polyarthritis Disease Model
    • 4
    • PDF
    Immuno-PCR assays for immunogenicity testing.
    • 34
    Differential effect of drug interference in immunogenicity assays.
    • 163
    Identification and inhibition of drug target interference in immunogenicity assays.
    • 58
    Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact.
    • 21
    The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab
    • 17
    Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development.
    • 73
    Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body
    • 34